Rapid Influenza Diagnostics Market Outlook:
Rapid Influenza Diagnostics Market size is valued at USD 1.5 billion in 2025 and is projected to reach USD 2.9 billion by the end of 2035, rising at a CAGR of approximately 8.7% during the forecast period, from, 2026-2035. In 2026, the industry size of rapid influenza diagnostics is estimated at USD 1.8 billion.
The primary growth drivers of the market are the growing need for timely and accurate detection of influenza infections to minimize transmission and patient treatment in clinical and institutional settings. Government-driven initiatives for increasing testing capabilities and improving outbreak management continue to provide impetus for investments in R&D and strengthening of the supply chain. However, as per a report by CDC September 2024, while RIDTs have the advantages of quick diagnosis and convenience, sensitivities are generally low, mostly ranging between 50% to 70% and reported at anywhere between 10% and 80% against viral culture or RT-PCR. The specificities are generally high, approximately 90% to 95% (with an 85% to 100% range), meaning that false negatives are more frequent than false positives.
Moreover, such a profile of performance necessitates continuous innovation and training towards the proper clinical application and interpretation, thereby suitable for the market. Besides, the supply chain involves sourcing reagents and raw materials and assembling diagnostic devices by FDA-approved manufacturers, using regulated import and export channels to maintain steady availability. Government efforts support the development of advanced molecular assays with improved sensitivity to enable rapid deployment across healthcare systems nationwide. This coordinated ecosystem supports market resilience and growth potential. Continued investment in domestic manufacturing is expected to reduce reliance on the global supply chain and improve readiness for seasonal or pandemic outbreaks.
